NUR SOYER, FERİT CELİK, MURAT TOMBULOGLU, FAHRİ SAHİN, GURAY SAYDAM, FİLİZ VURAL
Experimental and Clinical Transplantation - 2019;17(1):93-96
Objectives: The only known curative therapy for primary myelofibrosis is allogeneic hematopoietic stem cell transplant. Materials and Methods: We retrospectively evaluated 11 transplant procedures involving 10 patients (5 men and 5 women) diagnosed with primary myelofibrosis between 2005 and 2014. Results: The median age at the time of transplant was 60.5 years (range, 22-62 years). Stem cell sources were unrelated (n = 1) and related (n = 11) peripheral blood stem cells. Conditioning regimen was myeloablative for 8 and reduced intensity for 3 transplants. The median number of infused CD34+ cells was 6.8 × 106 cells/kg (range, 3.2-10.4 × 106 cells/kg). Neutrophil and pla telet engraftment occurred at median of 22 days (range, 12-31 days) and 19.5 days (range, 13-56 days). Acute and chronic graft-versus-host disease was seen in 4 of 11 allografts. Relapse and nonrelapse mortality rates were 20%. Six patients (60%) were still alive without disease after median follow-up of 68.5 months (range, 17-120 months). Median progression-free survival and overall survival were 61 months (range, 2-120 months) and 65 months (range, 2-120 months). Conclusions: Our results suggest that allogeneic hematopoietic stem cell transplant may provide a curative treatment for primary myelofibrosis patients. A myeloablative regimen seems to be effective and safe, especially for younger primary myelofibrosis patients.
